Latest News On Drug Costs

Latest California Healthline Stories

KFF Health News' 'What the Health?': Congress Punts to a Looming Lame-Duck Session

Congress left Washington for the campaign trail this week, but not before approving a spending bill that expires shortly before Christmas. Lawmakers will be busy after the election working on not just the legislation needed to keep the government running, but also several health programs set to expire. Meanwhile, Republicans continue to downplay abortion as Democrats press it as a campaign issue. Alice Miranda Ollstein of Politico, Lauren Weber of The Washington Post, and Joanne Kenen of Johns Hopkins University and Politico join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more.

KFF Health News' 'What the Health?': American Health Under Trump — Past, Present, and Future

Dreaming of a Trump victory, Republicans have a wish list of health policy changes — including loosening Affordable Care Act regulations to make cheaper coverage available and ending Medicare drug price negotiations. Meanwhile, after a publicly reported death stemming from a state abortion ban, Vice President Kamala Harris is emphasizing the consequences of Trump’s work to overturn Roe v. Wade. Tami Luhby of CNN, Shefali Luthra of The 19th, and Joanne Kenen of Politico and Johns Hopkins University join KFF Health News senior editor Emmarie Huetteman to discuss these stories and more.

California May Regulate and Restrict Pharmaceutical Brokers

California lawmakers are moving to rein in the pharmaceutical middlemen they say drive up costs and limit consumers’ choices. The bill sent to Gov. Gavin Newsom would require pharmacy benefit managers to be licensed in California and would ban some business practices. Newsom vetoed a previous effort three years ago.

With TV Drug Ads, What You See Is Not Necessarily What You Get

The pharmaceutical industry has invented a new art form: finding ways to make their wares seem like joyous must-have treatments, while often minimizing lackluster efficacy and risks.

New Lines of Attack Form Against the Affordable Care Act

While fighting potential fraud in government programs has long been a conservative rallying cry, recent criticisms of the Affordable Care Act represent a renewed line of attack on the program when repealing it is unlikely.

How Little Denmark Got Homegrown Giant Novo Nordisk To Lower Ozempic Prices

As Congress pushes for Medicare to cover payment for anti-obesity drugs, Denmark — Ozempic maker Novo Nordisk’s home — has limited coverage of the drug after cost overruns “emptied all the money boxes in the entire public health system.